Latest Apolipoprotein E Stories

A Swedish researcher said on Friday that mice who were fed junk food for nine months showed signs of developing the abnormal brain tangles strongly associated with Alzheimer's disease.A series of published papers by a researcher at Sweden's Karolinska Institute showed how a diet rich in fat, sugar and cholesterol could increase the risk of the most common type of dementia."On examining the brains of these mice, we found a chemical change not unlike that found in the Alzheimer...

SAN FRANCISCO, Aug. 20 /PRNewswire/ -- Emerging therapeutic strategies for Alzheimer's disease is the focus of the most recent edition of Neurotech Insights, the leading monthly industry newsletter covering drugs, devices and diagnostics for the brain and nervous system. This month's feature article reviews the competing hypotheses around the cause of Alzheimer's disease including: the beta amyloid theory, tau hypothesis, the APOE4 and vascular theory, anti-inflammatories, memory enhancers,...

CHICAGO _ Middle-aged married people who worry a lot have at least one thing to look forward to: Their risk of eventually developing Alzheimer's disease may be significantly less than carefree people of the same age who remain single. That's the take-home message from two studies presented jointly Wednesday in Chicago at the International Conference on Alzheimer's Disease. One study followed 1,449 men and women in Finland for an average of 21 years. It found that those who had a partner in...

Elan Corporation, plc (NYSE: ELN) and Wyeth (NYSE: WYE) today are presenting detailed results from the companies' 18-month Phase 2 study of bapineuzumab (AAB-001) in patients with mild to moderate Alzheimer's disease at the Alzheimer's Association's International Conference on Alzheimer's Disease 2008 in Chicago, Illinois. As previously announced, in the study, bapineuzumab appeared to have an acceptable safety profile and clinical activity in treating Alzheimer's disease. Potential efficacy...

If the incidence of Alzheimer's continues to increase at the current rate more than 81 million people worldwide will be suffering from the disease by 2040. However, according to a recent study, the risk of developing the disease may be significantly reduced by a combination of vitamins E and C and ibuprofen. Feelgoodforlife.com provides additional information on which anti-aging supplements help Alzheimer's and other forms of dementia. The current study, as reported by Arkansasmatters.com,...

By Delthia Ricks, Newsday, Melville, N.Y. Jun. 26--A gene that raises the risk of Alzheimer's disease by at least 45 percent, and possibly higher, has been identified by New York scientists and an international team of gene hunters. The discovery helps add context to what any layperson can see but what scientists have yet to fully explain: Most cases of Alzheimer's occur in people who are 65 and older. Until now, only one gene had been identified as a likely culprit -- ApoE4. Now,...

A gene that raises the risk of Alzheimer's disease by at least 45 percent, and possibly higher, has been identified by New York scientists and an international team of gene hunters. The discovery helps add context to what any layperson can see but what scientists have yet to fully explain: Most cases of Alzheimer's occur in people who are 65 and older. Until now, only one gene had been identified as a likely culprit _ ApoE4. Now, Philippe Marambaud of the Feinstein Institute for Medical...

U.S. researchers say they've found a protein that can predict Alzheimer's disease and the rate of progression of the human immunodeficiency virus. Investigators from The University of Texas Health Science Center at San Antonio led the study that provides more conclusive evidence of a link for the protein, called apoE4, to infectious diseases such as HIV. The scientists studied 1,300 European and African-American HIV-infected patients, comparing HIV clinical outcomes of individuals who have...

Elan and Wyeth have announced positive preliminary findings from a Phase II study of bapineuzumab in patients with mild to moderate Alzheimer's disease. In the 18-month trial, bapineuzumab appeared to have clinical activity in treating Alzheimer's disease. The study did not attain statistical significance on the primary efficacy endpoints in the overall study population. However, post-hoc analyses did show statistically significant and clinically meaningful benefits in important subgroups....

The much anticipated results of a clinical trial of one of the more promising Alzheimer's drugs, released June 17, were mixed at best. But in the Alzheimer's world that qualifies as a success -- and on Wall Street, it was a winner as well. Wyeth Pharmaceuticals (WYE) and Elan Corp. (ELN) announced that the Phase II trial of their jointly developed drug, bapineuzumab, did not attain statistically significant results in the overall group of 240 patients. But in a subset of patients that lacked...